Delcath Systems (DCTH) 10-K12 Mar 142013 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2013	Mar. 12, 2014	Jun. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'DELCATH SYSTEMS, INC.	'	'
Entity Central Index Key	'0000872912	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Non-accelerated Filer	'	'
Entity Public Float	'	'	$35,514,410
Entity Common Stock, Shares Outstanding	'	150,711,442	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Current assets	'	'
Cash and cash equivalents	$31,249	$23,726
Accounts receivables, net	349	144
Inventories	719	1,105
Prepaid expenses and other current assets	1,711	1,457
Total current assets	34,028	26,432
Property, plant and equipment, net	3,069	4,042
Total assets	37,097	30,474
Current liabilities	'	'
Accounts payable	582	939
Accrued expenses	3,740	5,790
Warrant liability	2,310	3,427
Total current liabilities	6,632	10,156
Long term liabilities	'	'
Deferred revenue	6	309
Accrued expenses	360	0
Total long term liabilities	366	309
Commitments and contingencies (Note 12)	'	'
Stockholders' equity	'	'
Preferred stock, $.01 par value; 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2013 and 2012	0	0
Common stock, $.01 par value; 170,000,000 shares authorized; 134,310,337 and 76,849,033 shares issued and 134,282,237 and 76,820,933 outstanding at December 31, 2013 and December 31, 2012, respectively	1,343	768
Additional paid-in capital	257,843	218,063
Accumulated deficit	-229,132	-198,808
Treasury stock, at cost; 28,100 shares at December 31, 2013 and December 31, 2012	-51	-51
Accumulated other comprehensive income	96	37
Total stockholders' equity	30,099	20,009
Total liabilities and stockholders' equity	$37,097	$30,474

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Stockholders' equity	'	'
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized (in shares)	170,000,000	170,000,000
Common stock, shares issued (in shares)	134,310,337	76,849,033
Common stock, shares outstanding (in shares)	134,282,237	76,820,933
Treasury stock, at cost (in shares)	28,100	28,100

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Loss (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Consolidated Statements of Operations and Comprehensive Loss [Abstract]	'	'	'
Revenue	$490	$346	$0
Other revenues	300	0	0
Total revenue	790	346	0
Costs of goods sold	-464	-39	0
Gross profit	326	307	0
Operating expenses	'	'	'
Selling, general and administrative	20,657	27,963	21,283
Research and development	12,688	26,215	25,173
Total operating expenses	33,345	54,178	46,456
Operating loss	-33,019	-53,871	-46,456
Change in fair value of warrant liability, net	2,756	2,159	15,566
Interest income	20	19	5
Other expense and interest expense	-81	-175	0
Net Loss	-30,324	-51,868	-30,885
Common share data:	'	'	'
Basic loss per share (in dollars per share)	($0.30)	($0.85)	($0.68)
Diluted loss per share (in dollars per share)	($0.31)	($0.85)	($0.68)
Weighted average number of basic common shares outstanding (in shares)	100,809,824	61,275,527	45,236,921
Weighted average number of diluted common shares outstanding (in shares)	105,104,177	61,275,527	45,236,921
Other comprehensive income (loss):	'	'	'
Foreign currency translation adjustments	59	37	0
Unrealized loss on securities	0	0	26
Other comprehensive income, total	59	37	26
Comprehensive loss	($30,265)	($51,831)	($30,859)

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Common Stock Issued [Member]	In Treasury [Member]	Additional Paid-in Capital [Member]	Accumulated deficit [Member]	Accumulated Other Comprehensive (loss) income [Member]	Total
In Thousands, except Share data, unless otherwise specified	Common Stock Issued [Member]	In Treasury [Member]	Additional Paid-in Capital [Member]	Accumulated deficit [Member]	Accumulated Other Comprehensive (loss) income [Member]	Total
Balance at Dec. 31, 2010	$430	($51)	$144,783	($116,055)	($26)	$29,081
Balance (in shares) at Dec. 31, 2010	43,028,146	-28,100	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Compensation expense for issuance of stock options	0	0	3,605	0	0	3,605
Compensation expense for issuance of restricted stock	2	0	652	0	0	654
Compensation expense for issuance of restricted stock (in shares)	173,212	0	'	'	'	'
Exercise of options, common stock surrendered upon restricted stock vesting	0	0	82	0	0	82
Exercise of options, common stock surrendered upon restricted stock vesting (in shares)	36,272	0	'	'	'	'
Sale of common stock, net of expenses	50	0	23,491	0	0	23,541
Sale of common stock, net of expenses (in shares)	5,000,000	0	'	'	'	'
Change in unrealized loss on investments	0	0	0	0	26	26
Foreign currency translation	'	'	'	'	'	0
Net loss	0	0	0	-30,885	0	-30,885
Balance at Dec. 31, 2011	482	-51	172,613	-146,940	0	26,104
Balance (in shares) at Dec. 31, 2011	48,237,630	-28,100	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Compensation expense for issuance of stock options	0	0	2,807	0	0	2,807
Compensation expense for issuance of restricted stock	4	0	1,014	0	0	1,018
Compensation expense for issuance of restricted stock (in shares)	408,687	0	'	'	'	'
Sale of common stock, net of expenses	252	0	36,995	0	0	37,247
Sale of common stock, net of expenses (in shares)	25,227,259	0	'	'	'	'
Change in unrealized loss on investments	'	'	'	'	'	0
Exercise of warrants	30	0	4,404	0	0	4,434
Exercise of warrants (in shares)	2,975,457	0	'	'	'	'
Fair value of warrants reclassified from liability to additional paid-in capital upon issuance and/or exercise	0	0	908	0	0	908
Fair value of warrants issued classified as liability	0	0	-678	0	0	-678
Foreign currency translation	0	0	0	0	37	37
Net loss	0	0	0	-51,868	0	-51,868
Balance at Dec. 31, 2012	768	-51	218,063	-198,808	37	20,009
Balance (in shares) at Dec. 31, 2012	76,849,033	-28,100	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Compensation expense for issuance of stock options	0	0	174	0	0	174
Compensation expense for issuance of restricted stock	1	0	116	0	0	117
Compensation expense for issuance of restricted stock (in shares)	137,651	0	'	'	'	'
Sale of common stock, net of expenses	572	0	40,888	0	0	41,460
Sale of common stock, net of expenses (in shares)	57,120,964	0	'	'	'	'
Change in unrealized loss on investments	'	'	'	'	'	0
Exercise of warrants	2	0	241	0	0	243
Exercise of warrants (in shares)	202,689	0	'	'	'	'
Fair value of warrants reclassified from liability to additional paid-in capital upon issuance and/or exercise	0	0	218	0	0	218
Fair value of warrants issued classified as liability	0	0	-1,857	0	0	-1,857
Foreign currency translation	0	0	0	0	59	59
Net loss	0	0	0	-30,324	0	-30,324
Balance at Dec. 31, 2013	$1,343	($51)	$257,843	($229,132)	$96	$30,099
Balance (in shares) at Dec. 31, 2013	134,310,337	-28,100	'	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:	'	'	'
Net loss	($30,324)	($51,868)	($30,885)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Stock option compensation expense	174	2,807	3,605
Restricted stock compensation expense	117	1,018	654
Depreciation expense	1,126	1,331	1,035
Loss on disposal of equipment	5	0	0
Warrant liability fair value adjustment	-2,756	-2,159	-15,566
Non-cash interest income	-1	2	0
Changes in assets and liabilities:	'	'	'
Decrease (increase) in prepaid expenses and other current assets	-235	-228	553
Decrease in investment in common stock	0	0	26
Decrease (increase) in accounts receivable	-211	-144	0
Decrease (increase) in inventories	391	-1,105	0
Increase (decrease) in accounts payable and accrued expenses	-2,445	331	3,206
Increase in deferred revenue and long-term accrued expenses	57	9	0
Net cash used in operating activities	-34,102	-50,006	-37,372
Cash flows from investing activities:	'	'	'
Purchase of property, plant, and equipment	-142	-2,120	-2,607
Purchase of short-term investments and marketable equity securities	0	0	-4,980
Proceeds from maturities of short-term investments	0	4,980	1,492
Net cash (used in) provided by investing activities	-142	2,860	-6,095
Cash flows from financing activities:	'	'	'
Net proceeds from sale of stock and exercise of stock options and warrants	41,702	45,058	23,623
Net cash provided by financing activities	41,702	45,058	23,623
Foreign currency effects on cash	65	37	0
(Decrease) increase in cash and cash equivalents	7,523	-2,051	-19,844
Cash and cash equivalents at beginning of period	23,726	25,777	45,621
Cash and cash equivalents at end of period	31,249	23,726	25,777
Supplemental non-cash activities:	'	'	'
Cashless exercise of stock options and shares surrendered upon restricted stock vesting	0	0	-61
Fair value of warrants issued	-1,857	4,055	0
Fair value of warrants reclassified from liability to additional paid-in capital upon exercise	$218	$908	$0

Description_of_Business

Description of Business	12 Months Ended
	Dec. 31, 2013
Description of Business [Abstract]	'
Description of Business	'
	-1	Description of Business

	Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Our proprietary drug/device combination product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan HDS)—is designed to administer high dose chemotherapy to the liver, while controlling the systemic exposure to those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers.

	Outside of the United States, our proprietary system to deliver and filter melphalan hydrochloride is marketed as a device under the trade name Delcath Hepatic CHEMOSAT^® Delivery System for Melphalan (CHEMOSAT). In April 2012, we obtained authorization to affix a CE Mark for the Generation Two CHEMOSAT system. The right to affix the CE mark allows the Company to market and sell the CHEMOSAT system in Europe.

	In the United States, the Melphalan HDS system is considered a combination drug and device product, and is regulated as a drug by the United States Food and Drug Administration (FDA). The Melphalan/HDS system has not been approved for sale in the United States.

	The Company has incurred losses since inception. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales. Management believes that its capital resources are adequate to fund operations through the first half of 2015, but anticipates that additional working capital will be required to continue operations. To the extent additional capital is not available when needed, the Company may be forced to abandon some or all of its development and commercialization efforts, which would have a material adverse effect on the prospects of the business. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainty of product development and clinical trial results; uncertainty regarding regulatory approval; technological uncertainty; uncertainty regarding patents and proprietary rights; comprehensive government regulations; limited commercial manufacturing, marketing or sales experience; and dependence on key personnel.

Basis_of_Consolidated_Financia

Basis of Consolidated Financial Statement Presentation	12 Months Ended
	Dec. 31, 2013
Basis of Condensed Consolidated Financial Statement Presentation [Abstract]	'
Basis of Consolidated Financial Statement Presentation	'
	-2	Basis of Consolidated Financial Statement Presentation

	The accounting and financial reporting policies of the Company conform to generally accepted accounting principles in the United States of America (GAAP). The preparation of consolidated financial statements in conformity with GAAP requires management to make assumptions and estimates that impact the amounts reported in the Company’s consolidated financial statements. The consolidated financial statements include the accounts of all entities controlled by Delcath. All significant inter-company accounts and transactions are eliminated.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	-3	Summary of Significant Accounting Policies

	Use of Estimates
	The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s condensed consolidated balance sheets and the amount of expenses reported for each of its periods presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for derivative instrument liabilities, stock-based compensation, valuation of inventory, impairment of long-lived assets, income taxes and operating expense accruals. Such assumptions and estimates are subject to change in the future as additional information becomes available or as circumstances are modified. Actual results could differ from these estimates.

	Cash Equivalents and Concentrations of Credit Risk
	The Company considers investments with original maturities of three months or less at date of acquisition to be cash equivalents. The Company has deposits that exceed amounts insured by the Federal Deposit Insurance Corporation (FDIC), however, the Company does not consider this a significant concentration of credit risk based on the strength of the financial institution.

	Investments
	Management determines the appropriate classification of securities at the time of purchase and reevaluates such classification as of each balance sheet date. The Company’s securities are classified as either available-for-sale or held-to-maturity. Investments classified as held-to-maturity are stated at amortized cost. Investments classified as available-for-sale are stated at fair value with the related unrealized gains and losses included in accumulated other comprehensive income (loss), a component of stockholders’ equity.

	Accounts Receivable
	Accounts receivable, principally trade, are generally due within 30 days and are stated at amounts due from customers. As the Company’s commercial activities expand, collections and payments from customers will be monitored and a provision for estimated credit losses will be created based upon historical experience and specific customer collection issues that may be identified. As of December 31, 2013, three customers individually accounted for greater than 10% of the Accounts Receivable balance.

	Inventories
	Inventories are valued at the lower of cost or market value using the first-in, first-out method. The reported net value of inventory includes finished saleable products, work-in-process, and raw materials that will be sold or used in future periods. The Company reserves for expired, obsolete, and slow-moving inventory.

	Prior to obtaining authorization to affix the CE Mark to its Generation Two CHEMOSAT system in April 2012, the Company expensed all of its inventory costs as research and development. Inventory as of December 31, 2013 includes finished goods and components relating to Generation Two of the CHEMOSAT system that have been purchased since April 2012. Therefore, as is common for companies transitioning from the development stage to commercial, to the extent that materials expensed prior to April 2012 are used in manufacturing finished goods for sale, the Company’s cost of goods sold will be adjusted accordingly.

	Property, Plant and Equipment
	Property, plant and equipment are recorded at cost, less accumulated depreciation. The Company provides for depreciation on a straight line basis over the estimated useful lives of the assets which range from three to seven years. Leasehold improvements will be amortized over the shorter of the lease term or the estimated useful life of the related assets when they are placed into service. Maintenance and repairs are charged to operations as incurred. Expenditures which substantially increase the useful lives of the related assets are capitalized.

	Derivative Instrument Liability
	The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of the hedging relationship designation. Accounting for changes in the fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2013 and 2012, the Company did not have any derivative instruments that were designated as hedges.

	Fair Value Measurements
	The Company adopted ASC 820, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 applies to reported balances that are required or permitted to be measured at fair value under existing accounting pronouncements; accordingly, the standard does not require any new fair value measurements of reported balances.

	ASC 820 emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

		·	Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access.
		·	Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals.
		·	Level 3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity’s own assumptions, as there is little, if any, related market activity.

	In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.

	Deferred Revenue
	Deferred revenue on the accompanying consolidated balance sheets includes payment received for product sales to a distributor. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied. The Company will recognize the revenue related to product sales when its obligations under the agreement have been satisfied. The Company recognized deferred revenue related to a research and distribution agreement upon the completion of certain requirements under the agreement.

	Revenue Recognition
	Revenue from product sales is generally recognized when all of the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred; product price is fixed or determinable; and collection of the resulting receivable is reasonably assured. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied. As of December 31, 2013, four customers individually accounted for greater than 10% of product revenue.

	Selling, General and Administrative
	Selling, general and administrative costs include personnel costs and related expenses for the Company’s sales, marketing, general management and administrative staff, recruitment, costs related to the Company’s commercialization efforts in Europe, professional service fees, professional license fees, business development and certain general legal activities.

	Research and Development
	Research and development costs include the costs of materials used for R&D and clinical trials, personnel costs associated with device and pharmaceutical R&D, clinical affairs, medical affairs, medical science liaisons, and regulatory affairs, costs of outside services and applicable indirect costs incurred in the development of the Company’s proprietary drug delivery system. All such costs are charged to expense when incurred.

	Stock Based Compensation
	The Company accounts for its share-based compensation in accordance with the provisions of ASC 718, which establishes accounting for equity instruments exchanged for employee services and ASC 505-50, which establishes accounting for equity-based payments to non-employees. Under the provisions of ASC 718, share-based compensation is measured at the grant date, based upon the fair value of the award, and is recognized as an expense over the option holders’ requisite service period (generally the vesting period of the equity grant). The Company is required to record compensation cost for all share-based payments granted to employees based upon the grant date fair value, estimated in accordance with the provisions of ASC 718. Under the provisions of ASC 505-50, measurement of compensation cost related to common shares issued to non-employees for services is based on the value of the services provided or the fair value of the shares issued. The measurement of non-employee stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests. The Company expensed its share-based compensation for share-based payments granted under the accelerated method, which treats each vesting tranche as if it were an individual grant.

	The Company periodically grants stock options for a fixed number of shares of common stock to its employees, directors and non-employee contractors, with an exercise price greater than or equal to the fair market value of Delcath’s common stock at the date of the grant. The Company estimates the fair value of stock options using an option pricing model. Key inputs used to estimate the fair value of stock options include the exercise price of the award, the expected post-vesting option life, the expected volatility of Delcath’s stock over the option’s expected term, the risk-free interest rate over the option’s expected term, and Delcath’s expected annual dividend yield. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards.

	Income Taxes
	The Company accounts for income taxes following the asset and liability method in accordance with the ASC 740 “Income Taxes.” Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled. See Note 13 for additional information.

	Net Loss per Common Share
	Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all common stock options and warrants are deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal. However, in certain periods in which the exercise price of the warrants was less than the last reported sales price of Delcath’s common stock on the final trading day of the period and there is a gain recorded pursuant to the change in fair value of the warrant derivative liability, the impact of gains related to the mark-to-market adjustment of the warrants outstanding at the end of the period is reversed and the treasury stock method is used to determine diluted earnings per share.

	The calculation of net loss and the number of shares used to compute basic and diluted earnings per share for the years ended December 31, 2013, 2012 and 2011 are as follows:

	(in thousands, except share data)		2013				2012				2011
	Net loss – basic		$	(30,324	)		$	(51,868	)		$	(30,885	)
Adjust for gain on warrant derivative liability			(1,835	)			—				—
Net loss - diluted			(32,159	)			(51,868	)			(30,885	)
Net loss per share – basic			(0.30	)			(0.85	)			(0.68	)
Weighted average shares outstanding – basic			100,809,824				61,275,527				45,236,921
Warrant exercises			4,294,353				—				—
Weighted average shares outstanding – diluted			105,104,177				61,275,527				45,236,921
Net loss per share – diluted			(0.31	)			(0.85	)			(0.68	)

For the years ended December 31, 2013, 2012, and 2011 the following potentially dilutive securities were excluded from the computation of diluted earnings per share (EPS) because their effects would be antidilutive.

Shares excluded from the computation of diluted EPS:

		2013				2012				2011
Stock options			4,035,143				4,788,887				4,129,749
Unvested restricted shares			325,722				501,468				193,532
Warrants			9,432,000				5,642,580				2,512,934
Total			13,792,865				10,932,935				6,836,215

Segment Information
The Company currently operates in one business segment, which is the development and commercialization of the CHEMOSAT/Melphalan HDS system. A single management team that reports to the Co-Chief Executive Officers comprehensively manages the business. Accordingly, the Company does not have separately reportable segments.

Foreign Currency and Currency Translation
Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange (losses)/gains in the statement of operations.

The assets and liabilities of the Company’s international subsidiaries are translated from their functional currencies into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions.

Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from translation of intercompany loans that are of a long-term-investment nature, are recorded in other comprehensive income.

Recently Adopted Accounting Pronouncements
In February 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2013-02 which requires additional disclosures regarding the reporting of reclassifications out of accumulated other comprehensive income. ASU 2013-02 requires an entity to present, either on the face of the statement where net income is presented or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required under GAAP to be reclassified to net income in its entirety in the same reporting period. This guidance is effective for reporting periods beginning after December 15, 2012. The Company adopted this guidance effective January 1, 2013. The Company’s adoption of this standard did not have a material impact on its consolidated financial statements.

In March 2013, the FASB issued ASU 2013-05, which permits an entity to release cumulative translation adjustments into net income when a reporting entity (parent) ceases to have a controlling financial interest in a subsidiary or group of assets that is a business within a foreign entity. Accordingly, the cumulative translation adjustment should be released into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided, or, if a controlling financial interest is no longer held. The revised standard is effective for fiscal years beginning after December 15, 2013; however, early adoption is permitted. The Company does not expect adoption of this ASU to materially impact its consolidated financial statements.

Inventories

Inventories	12 Months Ended
Inventories	Dec. 31, 2013
Inventories [Abstract]	'
Inventories	'
	-4	Inventories

	Inventories consist of:

	(in thousands)		31-Dec-13		31-Dec-12
	Raw materials		$	249	$	197
	Work-in-process			364		405
	Finished goods			106		503
	Total inventory		$	719	$	1,105

	Delcath transitioned from a development stage company to a commercial organization with operational activities in April 2012. A portion of the Company’s inventory was purchased prior to obtaining authorization to affix the CE Mark to its Generation Two CHEMOSAT system in April 2012, including components used in the kits sold during the year ended December 31, 2013. As a result, some of the costs of sales related to recognized and deferred revenue was expensed in earlier periods.

Prepaid_Expenses_and_Other_Cur

Prepaid Expenses and Other Current Assets	12 Months Ended
Prepaid Expenses and Other Current Assets	Dec. 31, 2013
Prepaid Expenses and Other Current Assets [Abstract]	'
Prepaid Expenses and Other Current Assets	'
	-5	Prepaid Expenses and Other Current Assets

	Prepaid expenses and other current assets include the following:

	(in thousands)		31-Dec-13		31-Dec-12
	Insurance premiums		$	407	$	232
	Professional fees			377		531
	Income tax credits receivable			326		305
	Kits for clinical use			287		81
	Other¹			314		308
	Total prepaid and other current assets		$	1,711	$	1,457

	1 Other consists of various prepaid expenses and other current assets, with no individual item accounting for more than 5% of prepaids and other current assets at December 31, 2013 and 2012.

Property_Plant_and_Equipment

Property, Plant, and Equipment	12 Months Ended
Property, Plant, and Equipment	Dec. 31, 2013
Property, Plant, and Equipment [Abstract]	'
Property, Plant, and Equipment	'
	(6)	Property, Plant, and Equipment

	Property, plant, and equipment consists of:

	(in thousands)		31-Dec-13			31-Dec-12
	Leaseholds		$	1,749		$	1,716
	Furniture			957			952
	Equipment			1,552			1,473
	Computers			2,143			2,141
	Buildings and land			603			603
				7,004			6,885
	Accumulated depreciation			(3,935	)		(2,843	)
			$	3,069		$	4,042

	Depreciation expense for the years ended December 31, 2013, 2012, and 2011 was $1.1 million, $1.3 million, and $1.0 million, respectively.

Current_Accrued_Expenses

Current Accrued Expenses	12 Months Ended
Current Accrued Expenses	Dec. 31, 2013
Current Accrued Expenses [Abstract]	'
Current Accrued Expenses	'
	-7	Current Accrued Expenses

	Current accrued expenses include the following:

	(in thousands)		31-Dec-13		31-Dec-12
	Compensation, excluding taxes		$	1,866	$	1,933
	Deferred rent			485		443
	Professional fees			360		1,438
	Contract Research Organization			—		1,283
	Other¹			1,029		693
	Total accrued liabilities		$	3,740	$	5,790

	1 Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at December 31, 2013 and 2012.

Restructuring_Charges

Restructuring Charges	12 Months Ended
	Dec. 31, 2013
Restructuring Charges [Abstract]	'
Restructuring Charges	'
	-8	Restructuring Expenses

	During the year ended December 31, 2013, the Company implemented restructurings of its workforce to better focus the Company’s organizational structure, increase efficiency and concentrate financial resources on its clinical development program and European commercialization activity. This resulted in a reduction in the Company’s workforce by 50 employees. As a result of termination benefits given to the impacted employees, the Company incurred a total cost of approximately $4.0 million which is included on the Consolidated Statements of Operations in both Selling, general and administrative expenses and Research and development expenses, as appropriate. Accrued severance expense at December 31, 2013 of $1.6 million is included in current accrued expenses and $0.4 million is included in long-term accrued expenses on the Consolidated Balance Sheets, for a total accrued severance expense of $2.0 million at December 31, 2013.

	(in thousands)		31-Dec-13
	Severance and restructuring expenses		$	3,974
	Restructuring expenses paid by December 31, 2013			(1,955	)
	Total restructuring expenses accrued as of December 31, 2013		$	2,019

	In November 2013, the Board of Directors approved an employee retention program for certain of its key employees, including the Company’s executive officers. The executive officers of the Company will be eligible to receive a cash retention bonus payment equal to fifty percent (50%) of their current annual salary if the executive officer remains employed by the Company through March 31, 2015. The expense related to this program is being accrued on a quarterly basis as the services are rendered and is included in current accrued expenses on the Consolidated Balance Sheets and Operations in both Selling, general and administrative expenses and Research and development expenses on the Consolidated Statements of Operations.

Assets_and_Liabilities_Measure

Assets and Liabilities Measured at Fair Value	12 Months Ended
Assets and Liabilities Measured at Fair Value	Dec. 31, 2013
Assets and Liabilities Measured at Fair Value [Abstract]	'
Assets and Liabilities Measured at Fair Value	'
	-9	Assets and Liabilities Measured at Fair Value

	Derivative Financial Instruments
	As disclosed in Note 10, the Company allocated proceeds to the warrants issued in connection with a private placement and recent public offering that were classified as liabilities and accounted for as a derivative instrument in accordance with ASC 815. The valuation of the warrants is determined using an option pricing model. This model uses inputs such as the underlying price of the shares issued when the warrant is exercised, volatility, risk free interest rate and expected life of the instrument. The Company has determined that the warrant derivative liability should be classified within Level 3 of the fair-value hierarchy by evaluating each input for the option pricing model against the fair-value hierarchy criteria and using the lowest level of input as the basis for the fair-value classification as called for in ASC 820. There are six inputs: closing price of Delcath stock on the day of evaluation; the exercise price of the warrants; the remaining term of the warrants; the volatility of Delcath’s stock over that term; annual rate of dividends; and the riskless rate of return. Of those inputs, the exercise price of the warrants and the remaining term are readily observable in the warrant agreements. The annual rate of dividends is based on the Company’s historical practice of not granting dividends. The closing price of Delcath stock would fall under Level 1 of the fair-value hierarchy as it is a quoted price in an active market (ASC 820-10). The riskless rate of return is a Level 2 input as defined in ASC 820-10, while the historical volatility is a Level 3 input as defined in ASC 820. Since the lowest level input is a Level 3, Delcath determined the warrant derivative liability is most appropriately classified within Level 3 of the fair value hierarchy.

	Money Market Funds
	The Company has determined that the inputs associated with the fair value determination are based on quoted prices (unadjusted) and as a result the investments are classified within Level 1 of the fair value hierarchy.

	The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2013 and 2012, aggregated by the level in the fair value hierarchy within which those measurements fall.

	Assets and Liabilities Measured at Fair Value on a Recurring Basis

			Level 1						Level 2				Level 3				Balance at
			Level 1						Level 2				Level 3				December 31,
	(in thousands)		2013			2012			2013		2012		2013		2012		2013			2012
	Assets
	Money market funds		$	1,956			$	1,967		—		—		—		—		$	1,956		$	1,967
	Liabilities
	Derivative instrument liabilities			—				—		—		—	$	2,310	$	3,427		$	2,310		$	3,427


	Fair Value Measurements Using Significant Unobservable
	Inputs (Level 3)
	(in thousands)		Derivative
	Balance at December 31, 2010		$	18,005
	Total change in the fair value of the liability included in earnings			(15,566	)
	Balance at December 31, 2011		$	2,439
	Total change in the fair value of the liability included in earnings			(2,159	)
	Fair value of warrants issued			4,055
	Fair value of warrants exercised or expired			(908	)
	Balance at December 31, 2012		$	3,427
	Total change in the fair value of the liability included in earnings			(2,756	)
	Fair value of warrants issued and exercised			1,639
	Balance at December 31, 2013		$	2,310

Stockholders_Equity

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2013
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
	-10	Stockholders’ Equity
	Stock Issuances

	In June 2009, the Company completed the sale of 0.9 million shares of its common stock and the issuance of warrants to purchase 1.0 million common shares (the “2009 Warrants”) pursuant to a subscription agreement with a single investor. The Company received proceeds of $3.0 million, with net cash proceeds after related expenses from this transaction of approximately $2.7 million. Of those proceeds, the Company allocated an estimated fair value of $2.2 million to the 2009 Warrants (see below). As required by the 2009 Warrant agreement, the exercise price of the warrants was adjusted following the Company’s October 2013 sale of common stock and warrants. At December 31, 2013, the 2009 Warrants were exercisable at $0.16 per share with 1.0 million warrants outstanding. The 2009 Warrants have a five-year term. The shares and warrants were issued pursuant to an effective registration statement on Form S-3.

	In July 2011, the Company completed the sale of 5.0 million shares of its common stock pursuant to an underwriting agreement, raising approximately $23.5 million after expenses. The shares were issued pursuant to an effective registration statement on Form S-3.

	In December 2011, the Company entered into a sales agreement (the “December 2011 Sales Agreement”) with Cowen and Company, LLC to sell shares of the Company’s common stock, par value $.01 per share, having aggregate sales proceeds of $39.8 million, from time to time, through an “at the market” equity offering program under which Cowen and Company, LLC will act as sales agent.

	In May 2012, the Company completed the sale of 15.3 million shares of its common stock and the issuance of warrants to purchase 4.6 million common shares (the “2012 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $21.5 million, with net cash proceeds after related expenses from this transaction of approximately $21.1 million. Of those proceeds, the Company allocated an estimated fair value of $3.4 million to the 2012 Warrants. As required by the 2012 Warrant agreement, the exercise price of the warrants was adjusted following the Company’s October 2013 sale of common stock and warrants. At December 31, 2013, the 2012 Warrants were exercisable at $0.16 per share with 4.4 million warrants outstanding. The 2012 Warrants have a three-year term. The shares and warrants were issued pursuant to an effective registration statement on Form S-3.

	In December 2012, the Company entered into a Common Stock Purchase Agreement (Purchase Agreement) with Terrapin Opportunity, L.P. (Terrapin) for a committed equity financing facility (CEFF) program. The Purchase Agreement provides that Terrapin is committed to purchase up to $35.0 million of our common stock over the 24-month term of the Purchase Agreement. During the year ended December 31, 2013 the Company sold approximately 5.6 million shares of its common stock through the program. The Company received proceeds of approximately $9.0 million, with net cash proceeds after related expenses from this transaction of approximately $8.9 million. The shares were issued pursuant to registration statement on Form S-3. The net proceeds will be used for general corporate purposes, including, but not limited to, commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures and working capital. In addition to the $9.0 million raised during the year ended December 31, 2013, the Company previously raised $2.1 million under the CEFF program. As a result, there was approximately $23.9 million available under this CEFF program as of December 31, 2013.

	During the three months ended March 31, 2013, the Company sold approximately 14.2 million shares of its common stock under the December 2011 Sales Agreement with Cowen and Company, LLC for proceeds of approximately $20.9 million, with net cash proceeds after related expenses of approximately $20.8 million, successfully completing the program. There are no shares of common stock of the Company remaining for sale under the December 2011 Sales Agreement.

	On March 13, 2013, the Company entered into a new sales agreement (the “March 2013 Sales Agreement”) with Cowen and Company, LLC to sell shares of the Company’s common stock, par value $.01 per share, having aggregate sales proceeds of $50,000,000, from time to time, through an “at the market” equity offering program under which Cowen and Company, LLC will act as sales agent. During the year ended December 31, 2013, the Company sold approximately 16.4 million shares of its common stock under the March 2013 Sales Agreement with Cowen and Company, LLC for proceeds of approximately $5.0 million, with net cash proceeds after related expenses of approximately $4.8 million. The shares were issued pursuant to registration statement Form S-3 (333-187230). The net proceeds will be used for general corporate purposes, including, but not limited to, commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures and working capital.

	In October 2013, the Company completed the sale of 21.0 million shares of its common stock and the issuance of warrants to purchase 9.4 million common shares (the “2013 Warrants”) pursuant to a placement agency agreement. The Company received proceeds of $7.5 million, with net cash proceeds after related expenses from this transaction of approximately $6.9 million. Of those proceeds, the Company allocated an estimated fair value of $1.9 million to the 2013 Warrants. The 2013 Warrants will become exercisable at $0.44 per share on April 30, 2014. The 2013 Warrants have a five-year term. The shares and warrants were issued pursuant to an effective registration statement on Form S-3.

	Stock Option Plans
	The Company established the 2004 Stock Incentive Plan and the 2009 Stock Incentive Plan (collectively, the “Plans”) under which 3,000,000, and 6,500,000 shares, respectively, were reserved for the issuance of stock options, stock appreciation rights, restricted stock, stock grants and other equity awards. In May 2012, the total number of shares of Delcath common stock reserved for issuance under the 2009 Stock Incentive Plan was increased by 2,300,000 shares, from 4,200,000 to 6,500,000 upon a favorable vote by the Company’s stockholders. A stock option grant allows the holder of the option to purchase a share of the Company’s common stock in the future at a stated price. The Plans are administered by the Compensation and Stock Option Committee of the board of directors which determines the individuals to whom awards shall be granted as well as the type, terms and conditions of each award, the option price and the duration of each award.

	Options granted under the Plans vest as determined by the Company’s Compensation and Stock Option Committee and expire over varying terms, but not more than ten years from the date of grant. Stock option activity for 2013, 2012, and 2011 is as follows:

			Number of				Exercise Price				Weighted Average				Weighted
			Options				per Share				Exercise Price				Average
															Remaining
															Life (Years)

	Outstanding at December 31, 2010			3,760,650			$	1.23-15.54			$	4.88				6.65
	Granted			671,326				2.00-9.18				5.72
	Expired			(120,000	)			3.28				3.28
	Forfeited			(136,900	)			1.40-9.93				4.65
	Exercised			(45,327	)			2.44-3.28				3.18
	Outstanding at December 31, 2011			4,129,749			$	1.23-15.54			$	5.09				6.38
	Granted			1,207,452				1.43-4.60				3.8
	Expired			(420,000	)			1.88-5.85				4.81
	Forfeited			(128,314	)			2.26-9.18				5.05
	Outstanding at December 31, 2012			4,788,887			$	1.23-15.54			$	4.79				6.88
	Granted			2,085,717				0.30-2.13				1.09
	Expired			(270,000	)			1.23-1.87				1.53
	Forfeited			(2,569,461	)			0.38-12.34				3.97
	Outstanding at December 31, 2013			4,035,143			$	0.30-15.54			$	3.62				2.13
				2,136,785			$	1.24-15.54			$	5.68				5.56
	Exercisable at December 31, 2013			2,136,785			$	1.24-15.54			$	5.68				5.56

	The estimated fair value of each option award granted was determined on the date of grant using an option pricing model with the following assumptions for option grants during the years ended December 31, 2013, 2012 and 2011:

			Year Ended December 31,
			2013				2012				2011
	Weighted average risk-free interest rate			1.3	%			1.11	%			2.07	%
	Weighted average expected volatility			92.31	%			79.89	%			74.64	%
	Expected volatility			86.16-97.21	%			77.37-84.81	%			73.88% - 79.11	%
	Dividend yield			0	%			0	%			0	%
	Weighted average expected option term (in years)			5.66				6.17				6
	Weighted average grant date fair value		$	0.81			$	2.59			$	3.79

	No dividend yield was assumed because the Company has never paid a cash dividend on its common stock and does not expect to pay dividends in the foreseeable future. Volatilities were developed using the Company’s historical volatility. The risk-free interest rate was developed using the U.S. Treasury yield for periods equal to the expected life of the stock options on the grant date. The expected option term for grants made during 2013 and the second half of 2012 is based on actual historical results. The expected option term for grants made prior to that was developed based on the mid-point between the vesting date and the expiration date of each respective grant as permitted under ASC 718. This method of determining the expected holding period was utilized because the Company did not have sufficient historical experience from which to estimate the period.

	A summary of the Company’s non-vested options to purchase shares as of December 31, 2013 and changes during the year ended December 31, 2013 and December 31, 2012 are presented below:

			Non-Vested Options
			Number of				Weighted
Options			Average
			Exercise Price

Non-vested at December 31, 2011				1,158,368			$	6.44
Granted			1,207,452				3.8
Vested			(570,518	)			6.38
Forfeited			(111,950	)			4.79
Non-vested at December 31, 2012			1,683,352			$	4.68
Granted			2,085,717				1.09
Vested			(686,232	)			5.38
Forfeited			(1,184,479	)			3.37
Non-vested at December 31, 2013			1,898,358				1.3

Compensation expense recognized relating to stock options granted to employees (in millions):

		2013				2012				2011
Selling, general and administrative		$	0.2			$	1.7			$	2.2
Research and development			0				1.1				1.4
Total		$	0.2			$	2.8			$	3.6

Additional compensation expense of $0.6 million, relating to the unvested portion of stock options granted, is expected to be recognized over a remaining average period of 1.25 years.

The aggregate intrinsic value of options outstanding and options exercisable at December 31, 2013 is $0. The aggregate intrinsic value represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s closing stock price of $0.26 as of December 31, 2013, which would have been received by the option holders had those option holders exercised their options as of that date.

A summary of the Company’s restricted stock activity as of December 31, 2013 and changes during the year ended December 31, 2013 and December 31, 2012 are presented below:

		Restricted Stock Activity
		Number of Shares				Weighted Average
						Grant Date Fair
						Value

Non-vested at December 31, 2011			193,532			$	5.84
Granted			429,720				2.83
Vested			(100,751	)			6.18
Forfeited			(21,033	)			4.39
Non-vested at December 31, 2012			501,468			$	3.26
Granted			276,250				0.42
Vested			(313,395	)			2.57
Forfeited			(138,601	)			4.32
Non-vested at December 31, 2013			325,722			$	1.05

Compensation expense recognized relating to restricted stock granted to employees (in millions):

		2013				2012				2011
Selling, general and administrative		$	0.2			$	0.7			$	0.5
Research and development			0				0.3				0.1
Total		$	0.2			$	1			$	0.6

Additional compensation expense of $0.1 million relating to the unvested portion of restricted stock granted, is expected to be recognized over a remaining average period of 0.7 years.

Warrants
The Company allocated part of the proceeds of public offerings in 2009, 2012 and 2013 of the Company’s common stock to warrants issued in connection with those transactions. The Company determined that these warrants should be classified as liabilities rather than equity as the terms of the warrants provide for potential adjustment in the exercise price and are therefore considered to be derivative instrument liabilities that are subject to mark-to-market adjustment each period. As of December 31, 2013, the 2009, 2012 and 2013 Warrants are classified as derivative instrument liabilities.

The valuation of the warrants is determined using an option pricing model. This model uses inputs such as the underlying price of the shares issued when the warrant is exercised, volatility, risk free interest rate and expected life of the instrument. The Company has determined that the warrant derivative liability should be classified within Level 3 of the fair-value hierarchy by evaluating each input for the model against the fair-value hierarchy criteria and using the lowest level of input as the basis for the fair-value classification as called for in ASC 820-10-35. There are six inputs: the closing price of the Company’s common stock on the day of evaluation; the exercise price of the warrants; the remaining term of the warrants; the volatility of Delcath’s stock over that term; annual rate of dividends; and the riskless rate of return. Of those inputs, the exercise price of the warrants and the remaining term are readily observable in the warrant agreements. The annual rate of dividends is based on our historical practice of not granting dividends. The closing price of the Company’s common stock would fall under Level 1 of the fair-value hierarchy as it is a quoted price in an active market (ASC 820-10-35-40). The riskless rate of return is a Level 2 input as defined in ASC 820-10-35-48, while the historical volatility is a Level 3 input as defined in ASC 820-10-55-22. Since the lowest level input is a Level 3, the Company determined the warrant derivative liability is most appropriately classified within Level 3 of the fair value hierarchy.

For the year ended December 31, 2013, the Company recorded pre-tax derivative instrument income of $2.8 million. The resulting derivative instrument liabilities totaled $2.3 million at December 31, 2013. Management expects that the Warrants will either be exercised or expire worthless. The fair value of the Warrants at December 31, 2013 was determined by using an option pricing model assuming the following:

		2013 Warrants				2012 Warrants				2009 Warrants
Expected volatility			90.75	%			106.77	%			128.5	%
Risk-free interest rates			1.63	%			0.26	%			0.1	%
Expected life (in years)			4.83				1.41				0.45

A summary of warrant activity is as follows:
		Warrants				Exercise Price				Weighted				Weighted Average
						per Share				Average				Remaining Life
										Exercise Price				(Years)

Outstanding at December 31, 2010			2,512,934			$	3.44-3.60			$	3.51				2.45
Issued			–
Exercised			–
Expired			–
Outstanding at December 31, 2011			2,512,934			$	3.44-3.60			$	3.51				1.45
Issued			6,523,120				1.49-3.03				1.65
Exercised			(2,975,457	)			1.49-1.65				1.49
Expired			(418,017	)			1.49				1.49
Outstanding at December 31, 2012			5,642,580			$	1.2			$	1.2				2.24
Issued			9,432,000				0.44				0.44
Exercised			(202,689	)			1.2				1.2
Expired			–
Outstanding at December 31, 2013			14,871,891			$	0.16-0.44			$	0.34				3.51

Loan_and_Security_Agreement

Loan and Security Agreement	12 Months Ended
	Dec. 31, 2013
Loan and Security Agreement [Abstract]	'
Loan and Security Agreement	'
	-11	Loan and Security Agreement

	In April 2012, the Company entered into a four-year Loan and Security Agreement (the “Credit Agreement“) with Silicon Valley Bank (“SVB”), as lender. The Credit Agreement consists of a revolving credit facility in an amount equal to the lesser of $20,000,000 and the Company’s Borrowing Base (as defined in the Credit Agreement). In order to draw down on the facility, the Company will need to have at least the greater of (i) $15,000,000 in cash and cash equivalents in its account with SVB plus the amount of all outstanding obligations of the Company owed to SVB and (ii) trailing 3 months Cash Burn (as defined in the Credit Agreement) plus the amount of all outstanding obligations of the Company owed to SVB. At December 31, 2013, the Company had not used any of the available funds.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2013
Commitments [Abstract]	'
Commitments	'
	-12	Commitments

	Operating Leases
	In February 2010, the Company entered into an agreement to lease (Initial Lease) 8,629 square feet of office space in New York, New York with an option to expand an additional 8,629 square feet. The term of the Initial Lease began in March, 2010 and provides for total annual base rental payments of $457,337 during years 1-3 and the first half of year 4 of the Initial Lease term, and of $491,853 during the second half of year 4 and years 5-7 of the Lease term. The Initial Lease also requires the Company to pay customary building operating expenses and a pro-rata share of real estate taxes.

	In September 2010, the Company exercised its option right under the Initial Lease and entered into an agreement to lease (Lease Amendment) an additional 8,629 square feet of office space in New York, New York. The term of the Lease Amendment began in January 2011 and will expire in March 2021. In addition, the Lease Amendment extends the term of the Initial Lease to March 2021. The Lease Amendment provides for annual base rent of $504,078 for years 1-5 and of $547,533 for years 6-11 of the Lease Amendment term. In addition, the Lease Amendment provides for total base rent on the space leased under the Initial Lease of $543,627 for the extended term of November 2017 – March 2021. Combined, the Initial Lease and the Lease Amendment provide for annual rent of $961,000 in 2012, $970,000 in 2013, $996,000 in 2014 and 2015, $1.0 million in 2016, and $1.1 million in 2017-2020.

	In August 2011, Delcath Systems Limited entered into an agreement of lease for an office and manufacturing facility located in the city of Galway, Ireland. This facility is approximately 19,200 square feet and is intended to be the location of Delcath’s European headquarters. The Lease is for a term of ten years, commencing August 2, 2011; although Delcath Limited has the option to terminate the Lease after the fifth year upon not less than six months’ notice. The Lease provides for fixed annual lease amounts payable in advance in equal quarterly installments. The annual lease amounts, which escalate annually, are as follows (USD conversions are based on the December 31, 2013 conversion rate): Year 1 – €106,051 ($146,009), Year 2 – €134,974 ($185,830), Year 3 – €159,077 ($219,015) and Years 4 and 5 – €183,179 ($252,198). Annual lease amounts in years 6 through 10 are subject to adjustment based upon the percentage increase in the consumer price index as published by the Ireland Central Statistics Office. Delcath Limited is also required to pay for customary building operating expenses. Delcath Limited’s payment obligations and performance of the Lease are guaranteed by Delcath.

	In May 2012, the Company entered into an agreement to purchase 10,320 square feet located at 566 Queensbury Avenue, Queensbury, NY (the “Facility”), which was previously leased. The purchase price for the Facility was $440,000 as stated in the initial lease agreement, which commenced on September 1, 2009.

	In June 2012, the Company entered into an agreement to lease 18,000 square feet at Suites 2 and 3 Country Club Road, Queensbury, NY for a three year period. This amends the initial lease at 2 Country Club Road, which commenced in November 2010. The location houses a portion of the Company’s research and manufacturing operations. The lease provides for annual base rent of $216,000, as well as the payment of customary building operating expenses and real estate taxes.

	In July 2012, the Company entered into a lease agreement for 95-97 Park Road in Queensbury, NY, agreeing to lease the 6,000 square feet at that location. The term began on July 18, 2012 and is effective for a one year period with an option to extend the lease for an additional year. The agreement provides for total annual base rent of $42,000.

	Future minimum lease payments under all operating leases at December 31, 2013 are as follows:

	(in thousands)		Future Lease Payment
	2014		$	1,469
	2015			1,338
	2016			1,183
	2017			1,052
	2018			1,091
			$	6,133

	Rent expense totaled approximately $1.5 million, $1.5 million and $1.2 million, for the years ended December 31, 2013, 2012 and 2011, respectively.

	Letters of Credit
	Under the terms of the lease agreement for office space in New York City, the Company is required to maintain a letter of credit in the amount of $881,297. The letter of credit expires on February 1, 2015 if not renewed by the Company.

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2013
Income Taxes [Abstract]	'
Income Taxes	'
	-13	Income Taxes

	The provision for income taxes differs from the amount computed by applying the statutory rate as follows:

			Year Ended December 31,
	(in thousands)		2013			2012			2011
	Income taxes using U.S. federal statutory rate		$	(10,309	)	$	(17,621	)	$	(10,501	)
	Amortization of gain on IP migration			781			754			–
	State income taxes, net of federal benefit			(1,390	)		(4,299	)		(3,418	)
	Foreign rate differential			2,761			3,716			52
	Valuation allowance			7,683			17,561			20,563
	Derivative charge			(937	)		(734	)		(5,292	)
	Stock option exercises and cancellations			1,589			310			102
	Research and development credits			(1,090	)		326			(1,633	)
	Other			912			(13	)		127
	Total		$	–		$	–		$	–

	Significant components of the Company’s deferred tax assets are as follows:

	(in thousands)		2013			2012
	Deferred tax assets:
	Employee compensation accruals		$	4,077		$	6,176
	Accrued liabilities			870			299
	Research tax credits			3,472			2,382
	Other			79			31
	Net operating losses			71,874			63,765
	Total deferred tax assets			80,372			72,653

	Deferred tax liability:
	Total deferred tax liabilities			–			–

	Valuation allowance			80,372			72,653
	Net deferred tax assets		$	–		$	–

	As of December 31, 2013 and December 31, 2012, the Company had net operating loss carryforwards for U.S. federal income tax purposes of approximately $158.4 million and $138.1 million, respectively. A portion of the federal amount, $8.6 million, is subject to an annual limitation of approximately $123,000 as a result of a change in the Company’s ownership through May 2003, as defined by Federal Internal Revenue Code Section 382 and the related income tax regulations. As a result of the limitation, approximately $152.3 million is available to offset future federal taxable income which will expire between 2018 and 2033. As of December 31, 2013 and December 31, 2012, the Company had net operating loss carryforwards for state and city income tax purposes of approximately $268.8 million and $231.0 million, respectively, which expire through 2033. As of December 31, 2013 and December 31, 2012, the Company had a net operating loss carryforward for foreign income tax purposes of $19.0 million and $17.4 million, respectively, which have indefinite carryforward periods.

	The Company has a tax benefit of approximately $1.0 million related to the exercise of non-qualified stock options. Pursuant to ASC 718, the benefit will be recognized and recorded to additional paid-in capital when the benefit is realized through the reduction of taxes payable. Management has established a 100% valuation allowance against the deferred tax assets as management does not believe it is more likely than not that these assets will be realized. The Company’s valuation allowance increased by approximately $7.7 million, $17.6 million, $20.5 million, $15.0 million, and $5.9 million in 2013, 2012, 2011, 2010, and 2009, respectively.

	The Company complies with the provisions of ASC 740-10 in accounting for its uncertain tax positions. ASC 740-10 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has determined that the Company has no significant uncertain tax positions requiring recognition under ASC 740-10.

	The Company is subject to income tax in the U.S., as well as various state and international jurisdictions. The Company has not been audited by the U.S. Internal Revenue Service, international tax authorities, or any states in connection with income taxes. The Company’s New York State tax returns have been subject to annual desk reviews which have resulted in insignificant adjustments to the related franchise tax liabilities and credits. The Company’s tax years generally remain open to examination for all federal, state and foreign tax matters until its net operating loss carryforwards are utilized and the applicable statutes of limitation have expired. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations.

	Delcath recognizes interest accrued related to unrecognized tax benefits and penalties, if incurred, as a component of income tax expense.

Quarterly_Financial_Data_Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
Quarterly Financial Data (Unaudited)	Dec. 31, 2013
Quarterly Financial Data (Unaudited) [Abstract]	'
Quarterly Financial Data (Unaudited)	'
	-14	Quarterly Financial Data (Unaudited)

	Set forth below is selected quarterly financial data for each of the quarters in the years ended December 31, 2013 and 2012.

			2013 Quarters Ended
	(in thousands except per share amounts)		31-Mar			30-Jun			30-Sep			31-Dec
	Operating loss		$	(10,202	)		(10,587	)		(6,702	)		(5,526	)
	Change in fair value of warrant liability, net			(2,272	)		5,115			(497	)		410
	Net loss			(12,845	)		(5,482	)		(7,206	)		(4,792	)
	Basic and diluted loss per share			(0.15	)		(0.06	)		(0.07	)		(0.04	)

			2012 Quarters Ended
	(in thousands except per share amounts)		31-Mar			30-Jun			30-Sep			31-Dec
	Operating loss		$	(14,554	)	$	(15,316	)	$	(12,175	)	$	(11,825	)
	Change in fair value of warrant liability, net			(338	)		917			446			1,134
	Net loss			(14,889	)		(14,512	)		(11,813	)		(10,657	)
	Basic and diluted loss per share			(0.31	)		(0.26	)		(0.18	)		(0.14	)

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	-15	Subsequent Events

	During the first quarter through February 28, 2014, the Company sold approximately 16.0 million shares of our common stock under the Sales Agreement through an “at the market” equity offering program for net proceeds of approximately $4.4 million before related expenses. The net proceeds will be used for general corporate purposes, including, but not limited to, commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures and working capital. As of March 11, 2014, the Company has approximately $40.4 million remaining under the program, assuming sufficient shares are available to be issued.

	The Company held a Special Meeting of Stockholders on February 24, 2014. The proposal to approve an amendment to Delcath’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of its Common Stock at a specific ratio within a range from 1-for-8 to 1-for-16, inclusive, on or prior to December 31, 2014 and to grant authorization to the Board of Directors to determine, in its discretion, whether to implement the reverse stock split, as well as its specific timing and ratio, was approved by shareholders.

	Delcath completed an evaluation of the impact of any subsequent events through the date financial statements were issued and determined there were no other subsequent events requiring disclosure in or adjustment to these financial statements.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2013

Summary of Significant Accounting Policies [Abstract]

Use of Estimates

The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s condensed consolidated balance sheets and the amount of expenses reported for each of its periods presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for derivative instrument liabilities, stock-based compensation, valuation of inventory, impairment of long-lived assets, income taxes and operating expense accruals. Such assumptions and estimates are subject to change in the future as additional information becomes available or as circumstances are modified. Actual results could differ from these estimates.

Cash Equivalents and Concentrations of Credit Risk

The Company considers investments with original maturities of three months or less at date of acquisition to be cash equivalents. The Company has deposits that exceed amounts insured by the Federal Deposit Insurance Corporation (FDIC), however, the Company does not consider this a significant concentration of credit risk based on the strength of the financial institution.

Investments

Management determines the appropriate classification of securities at the time of purchase and reevaluates such classification as of each balance sheet date. The Company’s securities are classified as either available-for-sale or held-to-maturity. Investments classified as held-to-maturity are stated at amortized cost. Investments classified as available-for-sale are stated at fair value with the related unrealized gains and losses included in accumulated other comprehensive income (loss), a component of stockholders’ equity.

Accounts Receivable

Accounts receivable, principally trade, are generally due within 30 days and are stated at amounts due from customers. As the Company’s commercial activities expand, collections and payments from customers will be monitored and a provision for estimated credit losses will be created based upon historical experience and specific customer collection issues that may be identified. As of December 31, 2013, three customers individually accounted for greater than 10% of the Accounts Receivable balance.

Inventories

Inventories are valued at the lower of cost or market value using the first-in, first-out method. The reported net value of inventory includes finished saleable products, work-in-process, and raw materials that will be sold or used in future periods. The Company reserves for expired, obsolete, and slow-moving inventory.

Prior to obtaining authorization to affix the CE Mark to its Generation Two CHEMOSAT system in April 2012, the Company expensed all of its inventory costs as research and development. Inventory as of December 31, 2013 includes finished goods and components relating to Generation Two of the CHEMOSAT system that have been purchased since April 2012. Therefore, as is common for companies transitioning from the development stage to commercial, to the extent that materials expensed prior to April 2012 are used in manufacturing finished goods for sale, the Company’s cost of goods sold will be adjusted accordingly.

Property, Plant and Equipment

Property, plant and equipment are recorded at cost, less accumulated depreciation. The Company provides for depreciation on a straight line basis over the estimated useful lives of the assets which range from three to seven years. Leasehold improvements will be amortized over the shorter of the lease term or the estimated useful life of the related assets when they are placed into service. Maintenance and repairs are charged to operations as incurred. Expenditures which substantially increase the useful lives of the related assets are capitalized.

Derivative Instrument Liability

The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of the hedging relationship designation. Accounting for changes in the fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2013 and 2012, the Company did not have any derivative instruments that were designated as hedges.

Fair Value Measurements

The Company adopted ASC 820, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 applies to reported balances that are required or permitted to be measured at fair value under existing accounting pronouncements; accordingly, the standard does not require any new fair value measurements of reported balances.

ASC 820 emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access.

Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals.

Level 3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity’s own assumptions, as there is little, if any, related market activity.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.

Deferred Revenue

Deferred revenue on the accompanying consolidated balance sheets includes payment received for product sales to a distributor. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied. The Company will recognize the revenue related to product sales when its obligations under the agreement have been satisfied. The Company recognized deferred revenue related to a research and distribution agreement upon the completion of certain requirements under the agreement.

Revenue Recognition

Revenue from product sales is generally recognized when all of the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred; product price is fixed or determinable; and collection of the resulting receivable is reasonably assured. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied. As of December 31, 2013, four customers individually accounted for greater than 10% of product revenue.

Selling, General and Administrative

Selling, general and administrative costs include personnel costs and related expenses for the Company’s sales, marketing, general management and administrative staff, recruitment, costs related to the Company’s commercialization efforts in Europe, professional service fees, professional license fees, business development and certain general legal activities.

Research and Development

Research and development costs include the costs of materials used for R&D and clinical trials, personnel costs associated with device and pharmaceutical R&D, clinical affairs, medical affairs, medical science liaisons, and regulatory affairs, costs of outside services and applicable indirect costs incurred in the development of the Company’s proprietary drug delivery system. All such costs are charged to expense when incurred.

Stock Based Compensation

The Company accounts for its share-based compensation in accordance with the provisions of ASC 718, which establishes accounting for equity instruments exchanged for employee services and ASC 505-50, which establishes accounting for equity-based payments to non-employees. Under the provisions of ASC 718, share-based compensation is measured at the grant date, based upon the fair value of the award, and is recognized as an expense over the option holders’ requisite service period (generally the vesting period of the equity grant). The Company is required to record compensation cost for all share-based payments granted to employees based upon the grant date fair value, estimated in accordance with the provisions of ASC 718. Under the provisions of ASC 505-50, measurement of compensation cost related to common shares issued to non-employees for services is based on the value of the services provided or the fair value of the shares issued. The measurement of non-employee stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests. The Company expensed its share-based compensation for share-based payments granted under the accelerated method, which treats each vesting tranche as if it were an individual grant.

The Company periodically grants stock options for a fixed number of shares of common stock to its employees, directors and non-employee contractors, with an exercise price greater than or equal to the fair market value of Delcath’s common stock at the date of the grant. The Company estimates the fair value of stock options using an option pricing model. Key inputs used to estimate the fair value of stock options include the exercise price of the award, the expected post-vesting option life, the expected volatility of Delcath’s stock over the option’s expected term, the risk-free interest rate over the option’s expected term, and Delcath’s expected annual dividend yield. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards.

Income Taxes

The Company accounts for income taxes following the asset and liability method in accordance with the ASC 740 “Income Taxes.” Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled. See Note 13 for additional information.

Net Loss per Common Share

Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all common stock options and warrants are deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal. However, in certain periods in which the exercise price of the warrants was less than the last reported sales price of Delcath’s common stock on the final trading day of the period and there is a gain recorded pursuant to the change in fair value of the warrant derivative liability, the impact of gains related to the mark-to-market adjustment of the warrants outstanding at the end of the period is reversed and the treasury stock method is used to determine diluted earnings per share.

The calculation of net loss and the number of shares used to compute basic and diluted earnings per share for the years ended December 31, 2013, 2012 and 2011 are as follows:

(in thousands, except share data)

2013

2012

2011

Net loss – basic

(30,324

)

(51,868

)

(30,885

)

Adjust for gain on warrant derivative liability

(1,835

)

—

Net loss - diluted

(32,159

)

(51,868

)

(30,885

)

Net loss per share – basic

(0.30

)

(0.85

)

(0.68

)

Weighted average shares outstanding – basic

100,809,824

61,275,527

45,236,921

Warrant exercises

4,294,353

—

Weighted average shares outstanding – diluted

105,104,177

61,275,527

45,236,921

Net loss per share – diluted

(0.31

)

(0.85

)

(0.68

)

For the years ended December 31, 2013, 2012, and 2011 the following potentially dilutive securities were excluded from the computation of diluted earnings per share (EPS) because their effects would be antidilutive.

Shares excluded from the computation of diluted EPS:

2013

2012

2011

Stock options

4,035,143

4,788,887

4,129,749

Unvested restricted shares

325,722

501,468

193,532

Warrants

9,432,000

5,642,580

2,512,934

Total

13,792,865

10,932,935

6,836,215

Segment Information

The Company currently operates in one business segment, which is the development and commercialization of the CHEMOSAT/Melphalan HDS system. A single management team that reports to the Co-Chief Executive Officers comprehensively manages the business. Accordingly, the Company does not have separately reportable segments.

Foreign Currency and Currency Translation

Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange (losses)/gains in the statement of operations.

The assets and liabilities of the Company’s international subsidiaries are translated from their functional currencies into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions.

Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from translation of intercompany loans that are of a long-term-investment nature, are recorded in other comprehensive income.

Recently Adopted Accounting Pronouncements

In February 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2013-02 which requires additional disclosures regarding the reporting of reclassifications out of accumulated other comprehensive income. ASU 2013-02 requires an entity to present, either on the face of the statement where net income is presented or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required under GAAP to be reclassified to net income in its entirety in the same reporting period. This guidance is effective for reporting periods beginning after December 15, 2012. The Company adopted this guidance effective January 1, 2013. The Company’s adoption of this standard did not have a material impact on its consolidated financial statements.

In March 2013, the FASB issued ASU 2013-05, which permits an entity to release cumulative translation adjustments into net income when a reporting entity (parent) ceases to have a controlling financial interest in a subsidiary or group of assets that is a business within a foreign entity. Accordingly, the cumulative translation adjustment should be released into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided, or, if a controlling financial interest is no longer held. The revised standard is effective for fiscal years beginning after December 15, 2013; however, early adoption is permitted. The Company does not expect adoption of this ASU to materially impact its consolidated financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'
Calculation of net loss and number of shares used to compute basic and diluted earnings per share	'
	The calculation of net loss and the number of shares used to compute basic and diluted earnings per share for the years ended December 31, 2013, 2012 and 2011 are as follows:

	(in thousands, except share data)	2013			2012			2011
	Net loss – basic	$	(30,324	)	$	(51,868	)	$	(30,885	)
	Adjust for gain on warrant derivative liability		(1,835	)		—			—
	Net loss - diluted		(32,159	)		(51,868	)		(30,885	)
	Net loss per share – basic		(0.30	)		(0.85	)		(0.68	)
	Weighted average shares outstanding – basic		100,809,824			61,275,527			45,236,921
	Warrant exercises		4,294,353			—			—
	Weighted average shares outstanding – diluted		105,104,177			61,275,527			45,236,921
	Net loss per share – diluted		(0.31	)		(0.85	)		(0.68	)
Shares excluded from the computation of diluted EPS	'
	Shares excluded from the computation of diluted EPS:

		2013			2012			2011
	Stock options		4,035,143			4,788,887			4,129,749
	Unvested restricted shares		325,722			501,468			193,532
	Warrants		9,432,000			5,642,580			2,512,934
	Total		13,792,865			10,932,935			6,836,215

Inventories_Tables

Inventories (Tables)	12 Months Ended
Inventories (Tables)	Dec. 31, 2013
Inventories [Abstract]	'
Schedule of inventories	'
	Inventories consist of:

	(in thousands)	31-Dec-13		31-Dec-12
	Raw materials	$	249	$	197
	Work-in-process		364		405
	Finished goods		106		503
	Total inventory	$	719	$	1,105

Prepaid_Expenses_and_Other_Cur1

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
Prepaid Expenses and Other Current Assets (Tables)	Dec. 31, 2013
Prepaid Expenses and Other Current Assets [Abstract]	'
Prepaid expenses and other current assets	'
	Prepaid expenses and other current assets include the following:

	(in thousands)	31-Dec-13		31-Dec-12
	Insurance premiums	$	407	$	232
	Professional fees		377		531
	Income tax credits receivable		326		305
	Kits for clinical use		287		81
	Other¹		314		308
	Total prepaid and other current assets	$	1,711	$	1,457

	1 Other consists of various prepaid expenses and other current assets, with no individual item accounting for more than 5% at December 31, 2013 and 2012.

Property_Plant_and_Equipment_T

Property, Plant, and Equipment (Tables)	12 Months Ended
Property, Plant, and Equipment (Tables)	Dec. 31, 2013
Property, Plant, and Equipment [Abstract]	'
Components of property, plant and equipment	'
	Property, plant, and equipment consists of:

	(in thousands)	31-Dec-13			31-Dec-12
	Leaseholds	$	1,749		$	1,716
	Furniture		957			952
	Equipment		1,552			1,473
	Computers		2,143			2,141
	Buildings and land		603			603
			7,004			6,885
	Accumulated depreciation		(3,935	)		(2,843	)
		$	3,069		$	4,042

Current_Accrued_Expenses_Table

Current Accrued Expenses (Tables)	12 Months Ended
Current Accrued Expenses (Tables)	Dec. 31, 2013
Current Accrued Expenses [Abstract]	'
Schedule of current accrued expenses	'
	Current accrued expenses include the following:

	(in thousands)	31-Dec-13		31-Dec-12
	Compensation, excluding taxes	$	1,866	$	1,933
	Deferred rent		485		443
	Professional fees		360		1,438
	Contract Research Organization		—		1,283
	Other¹		1,029		693
	Total accrued liabilities	$	3,740	$	5,790

Restructuring_Charges_Tables

Restructuring Charges (Tables)	12 Months Ended
	Dec. 31, 2013
Restructuring Charges [Abstract]	'
Schedule of restructuring and related costs	'
	Accrued severance expense at December 31, 2013 of $1.6 million is included in current accrued expenses and $0.4 million is included in long-term accrued expenses on the Consolidated Balance Sheets, for a total accrued severance expense of $2.0 million at December 31, 2013.

	(in thousands)	31-Dec-13
	Severance and restructuring expenses	$	3,974
	Restructuring expenses paid by December 31, 2013		(1,955	)
	Total restructuring expenses accrued as of December 31, 2013	$	2,019

Assets_and_Liabilities_Measure1

Assets and Liabilities Measured at Fair Value (Tables)	12 Months Ended
Assets and Liabilities Measured at Fair Value (Tables)	Dec. 31, 2013
Assets and Liabilities Measured at Fair Value [Abstract]	'
Assets and Liabilities Measured at Fair Value on a Recurring Basis	'
	The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2013 and 2012, aggregated by the level in the fair value hierarchy within which those measurements fall.

	Assets and Liabilities Measured at Fair Value on a Recurring Basis

		Level 1						Level 2				Level 3				Balance at
		Level 1						Level 2				Level 3				December 31,
	(in thousands)	2013			2012			2013		2012		2013		2012		2013			2012
	Assets
	Money market funds	$	1,956			$	1,967		—		—		—		—		$	1,956		$	1,967
	Liabilities
	Derivative instrument liabilities		—				—		—		—	$	2,310	$	3,427		$	2,310		$	3,427
Fair Value Measurements Using Significant Unobservable Inputs	'
	Fair Value Measurements Using Significant Unobservable
	Inputs (Level 3)
	(in thousands)	Derivative
	Balance at December 31, 2010	$	18,005
	Total change in the fair value of the liability included in earnings		(15,566	)
	Balance at December 31, 2011	$	2,439
	Total change in the fair value of the liability included in earnings		(2,159	)
	Fair value of warrants issued		4,055
	Fair value of warrants exercised or expired		(908	)
	Balance at December 31, 2012	$	3,427
	Total change in the fair value of the liability included in earnings		(2,756	)
	Fair value of warrants issued and exercised		1,639
	Balance at December 31, 2013	$	2,310

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
Stockholders' Equity (Tables)	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Stock option activity	'
	Options granted under the Plans vest as determined by the Company’s Compensation and Stock Option Committee and expire over varying terms, but not more than ten years from the date of grant. Stock option activity for 2013, 2012, and 2011 is as follows:

		Number of			Exercise Price			Weighted Average			Weighted
		Options			per Share			Exercise Price			Average
											Remaining
											Life (Years)

	Outstanding at December 31, 2010		3,760,650		$	1.23-15.54		$	4.88			6.65
	Granted		671,326			2.00-9.18			5.72
	Expired		(120,000	)		3.28			3.28
	Forfeited		(136,900	)		1.40-9.93			4.65
	Exercised		(45,327	)		2.44-3.28			3.18
	Outstanding at December 31, 2011		4,129,749		$	1.23-15.54		$	5.09			6.38
	Granted		1,207,452			1.43-4.60			3.8
	Expired		(420,000	)		1.88-5.85			4.81
	Forfeited		(128,314	)		2.26-9.18			5.05
	Outstanding at December 31, 2012		4,788,887		$	1.23-15.54		$	4.79			6.88
	Granted		2,085,717			0.30-2.13			1.09
	Expired		(270,000	)		1.23-1.87			1.53
	Forfeited		(2,569,461	)		0.38-12.34			3.97
	Outstanding at December 31, 2013		4,035,143		$	0.30-15.54		$	3.62			2.13
			2,136,785		$	1.24-15.54		$	5.68			5.56
	Exercisable at December 31, 2013		2,136,785		$	1.24-15.54		$	5.68			5.56
Non-vested options	'
	A summary of the Company’s non-vested options to purchase shares as of December 31, 2013 and changes during the year ended December 31, 2013 and December 31, 2012 are presented below:

		Non-Vested Options
		Number of			Weighted
		Options			Average
					Exercise Price

	Non-vested at December 31, 2011		1,158,368		$	6.44
	Granted		1,207,452			3.8
	Vested		(570,518	)		6.38
	Forfeited		(111,950	)		4.79
	Non-vested at December 31, 2012		1,683,352		$	4.68
	Granted		2,085,717			1.09
	Vested		(686,232	)		5.38
	Forfeited		(1,184,479	)		3.37
	Non-vested at December 31, 2013		1,898,358			1.3
Restricted stock activity	'
	A summary of the Company’s restricted stock activity as of December 31, 2013 and changes during the year ended December 31, 2013 and December 31, 2012 are presented below:

		Restricted Stock Activity
		Number of Shares			Weighted Average
					Grant Date Fair
					Value

	Non-vested at December 31, 2011		193,532		$	5.84
	Granted		429,720			2.83
	Vested		(100,751	)		6.18
	Forfeited		(21,033	)		4.39
	Non-vested at December 31, 2012		501,468		$	3.26
	Granted		276,250			0.42
	Vested		(313,395	)		2.57
	Forfeited		(138,601	)		4.32
	Non-vested at December 31, 2013		325,722		$	1.05
Warrant activity	'
	A summary of warrant activity is as follows:
		Warrants			Exercise Price			Weighted			Weighted Average
					per Share			Average			Remaining Life
								Exercise Price			(Years)

	Outstanding at December 31, 2010		2,512,934		$	3.44-3.60		$	3.51			2.45
	Issued		–
	Exercised		–
	Expired		–
	Outstanding at December 31, 2011		2,512,934		$	3.44-3.60		$	3.51			1.45
	Issued		6,523,120			1.49-3.03			1.65
	Exercised		(2,975,457	)		1.49-1.65			1.49
	Expired		(418,017	)		1.49			1.49
	Outstanding at December 31, 2012		5,642,580		$	1.2		$	1.2			2.24
	Issued		9,432,000			0.44			0.44
	Exercised		(202,689	)		1.2			1.2
	Expired		–
	Outstanding at December 31, 2013		14,871,891		$	0.16-0.44		$	0.34			3.51
Stock Options [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Assumptions used to determine the fair value of stock options	'
	The estimated fair value of each option award granted was determined on the date of grant using an option pricing model with the following assumptions for option grants during the years ended December 31, 2013, 2012 and 2011:

		Year Ended December 31,
		2013			2012			2011
	Weighted average risk-free interest rate		1.3	%		1.11	%		2.07	%
	Weighted average expected volatility		92.31	%		79.89	%		74.64	%
	Expected volatility		86.16-97.21	%		77.37-84.81	%		73.88% - 79.11	%
	Dividend yield		0	%		0	%		0	%
	Weighted average expected option term (in years)		5.66			6.17			6
	Weighted average grant date fair value	$	0.81		$	2.59		$	3.79
Compensation expense recognized granted to employees	'
	Compensation expense recognized relating to stock options granted to employees (in millions):

		2013			2012			2011
	Selling, general and administrative	$	0.2		$	1.7		$	2.2
	Research and development		0			1.1			1.4
	Total	$	0.2		$	2.8		$	3.6
Restricted Stock [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Compensation expense recognized granted to employees	'
	Compensation expense recognized relating to restricted stock granted to employees (in millions):

		2013			2012			2011
	Selling, general and administrative	$	0.2		$	0.7		$	0.5
	Research and development		0			0.3			0.1
	Total	$	0.2		$	1		$	0.6
Warrant [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Assumptions used to determine the fair value of stock options	'
	The fair value of the Warrants at December 31, 2013 was determined by using an option pricing model assuming the following:

		2013 Warrants			2012 Warrants			2009 Warrants
	Expected volatility		90.75	%		106.77	%		128.5	%
	Risk-free interest rates		1.63	%		0.26	%		0.1	%
	Expected life (in years)		4.83			1.41			0.45

Commitments_Tables

Commitments (Tables)	12 Months Ended
Commitments (Tables)	Dec. 31, 2013
Commitments [Abstract]	'
Future minimum lease payments under all operating leases	'
	Future minimum lease payments under all operating leases at December 31, 2013 are as follows:

	(in thousands)	Future Lease Payment
	2014	$	1,469
	2015		1,338
	2016		1,183
	2017		1,052
	2018		1,091
		$	6,133

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2013
Income Taxes [Abstract]	'
Income tax reconciliation	'
	The provision for income taxes differs from the amount computed by applying the statutory rate as follows:

		Year Ended December 31,
	(in thousands)	2013			2012			2011
	Income taxes using U.S. federal statutory rate	$	(10,309	)	$	(17,621	)	$	(10,501	)
	Amortization of gain on IP migration		781			754			–
	State income taxes, net of federal benefit		(1,390	)		(4,299	)		(3,418	)
	Foreign rate differential		2,761			3,716			52
	Valuation allowance		7,683			17,561			20,563
	Derivative charge		(937	)		(734	)		(5,292	)
	Stock option exercises and cancellations		1,589			310			102
	Research and development credits		(1,090	)		326			(1,633	)
	Other		912			(13	)		127
	Total	$	–		$	–		$	–
Significant components of deferred tax assets	'
	Significant components of the Company’s deferred tax assets are as follows:

	(in thousands)	2013			2012
	Deferred tax assets:
	Employee compensation accruals	$	4,077		$	6,176
	Accrued liabilities		870			299
	Research tax credits		3,472			2,382
	Other		79			31
	Net operating losses		71,874			63,765
	Total deferred tax assets		80,372			72,653

	Deferred tax liability:
	Total deferred tax liabilities		–			–

	Valuation allowance		80,372			72,653
	Net deferred tax assets	$	–		$	–

Quarterly_Financial_Data_Unaud1

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
Quarterly Financial Data (Unaudited) (Tables)	Dec. 31, 2013
Quarterly Financial Data (Unaudited) [Abstract]	'
Selected quarterly financial data	'
	Set forth below is selected quarterly financial data for each of the quarters in the years ended December 31, 2013 and 2012.

		2013 Quarters Ended
	(in thousands except per share amounts)	31-Mar			30-Jun			30-Sep			31-Dec
	Operating loss	$	(10,202	)		(10,587	)		(6,702	)		(5,526	)
	Change in fair value of warrant liability, net		(2,272	)		5,115			(497	)		410
	Net loss		(12,845	)		(5,482	)		(7,206	)		(4,792	)
	Basic and diluted loss per share		(0.15	)		(0.06	)		(0.07	)		(0.04	)

		2012 Quarters Ended
	(in thousands except per share amounts)	31-Mar			30-Jun			30-Sep			31-Dec
	Operating loss	$	(14,554	)	$	(15,316	)	$	(12,175	)	$	(11,825	)
	Change in fair value of warrant liability, net		(338	)		917			446			1,134
	Net loss		(14,889	)		(14,512	)		(11,813	)		(10,657	)
	Basic and diluted loss per share		(0.31	)		(0.26	)		(0.18	)		(0.14	)

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Segment	Dec. 31, 2012	Dec. 31, 2011
Cash Equivalents and Concentrations of Credit Risk [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Maximum number of months of investments with original maturities from date of acquisition to be cash equivalents	'	'	'	'	'	'	'	'	'3 months	'	'
Calculation of net loss and the number of shares used to compute basic and diluted earnings per share [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Net loss - basic	($4,792)	($7,206)	($5,482)	($12,845)	($10,657)	($11,813)	($14,512)	($14,889)	($30,324)	($51,868)	($30,885)
Adjust for gain on warrant derivative liability	'	'	'	'	'	'	'	'	-1,835	0	0
Net loss - diluted	'	'	'	'	'	'	'	'	($32,159)	($51,868)	($30,885)
Net loss per share - basic (in dollars per share)	($0.04)	($0.07)	($0.06)	($0.15)	($0.14)	($0.18)	($0.26)	($0.31)	($0.30)	($0.85)	($0.68)
Weighted average shares outstanding - basic (in shares)	'	'	'	'	'	'	'	'	100,809,824	61,275,527	45,236,921
Warrant exercises (in shares)	'	'	'	'	'	'	'	'	4,294,353	0	0
Weighted average shares outstanding - diluted (in dollars per share)	'	'	'	'	'	'	'	'	105,104,177	61,275,527	45,236,921
Net loss per share - diluted (in dollars per share)	'	'	'	'	'	'	'	'	($0.31)	($0.85)	($0.68)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Shares excluded from the computation of diluted EPS (in shares)	'	'	'	'	'	'	'	'	13,792,865	10,932,935	6,836,215
Segment Information [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Number of business segments	'	'	'	'	'	'	'	'	1	'	'
Stock options [Member]	'	'	'	'	'	'	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Shares excluded from the computation of diluted EPS (in shares)	'	'	'	'	'	'	'	'	4,035,143	4,788,887	4,129,749
Unvested restricted shares [Member]	'	'	'	'	'	'	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Shares excluded from the computation of diluted EPS (in shares)	'	'	'	'	'	'	'	'	325,722	501,468	193,532
Warrants [Member]	'	'	'	'	'	'	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Shares excluded from the computation of diluted EPS (in shares)	'	'	'	'	'	'	'	'	9,432,000	5,642,580	2,512,934
Minimum [Member]	'	'	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Estimated useful lives	'	'	'	'	'	'	'	'	'3 years	'	'
Maximum [Member]	'	'	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Estimated useful lives	'	'	'	'	'	'	'	'	'7 years	'	'
Accounts Receivable [Member] \| Customer Concentration Risk [Member]	'	'	'	'	'	'	'	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Customers individually accounted for greater than 10%	'	'	'	'	'	'	'	'	3	'	'
Product revenue [Member] \| Customer Concentration Risk [Member]	'	'	'	'	'	'	'	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Customers individually accounted for greater than 10%	'	'	'	'	'	'	'	'	4	'	'

Inventories_Details

Inventories (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Inventories [Abstract]	'	'
Raw materials	$249	$197
Work-in-process	364	405
Finished goods	106	503
Total inventory	$719	$1,105

Prepaid_Expenses_and_Other_Cur2

Prepaid Expenses and Other Current Assets (Details) (USD $)	Dec. 31, 2013		Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012
Prepaid expenses and other current assets [Abstract]	'		'
Insurance premiums	$407		$232
Professional fees	377		531
Income tax credits receivable	326		305
Kits for clinical use	287		81
Other	314	[1]	308	[1]
Total prepaid and other current assets	$1,711		$1,457
Maximum percentage of prepaid expenses and other current assets (in hundredths)	5.00%		5.00%

[1]	Other consists of various prepaid expenses and other current assets, with no individual item accounting for more than 5% at December 31, 2013 and 2012.

Property_Plant_and_Equipment_D

Property, Plant, and Equipment (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property, Plant and Equipment [Line Items]	'	'	'
Property, plant and equipment, gross	$7,004	$6,885	'
Accumulated depreciation	-3,935	-2,843	'
Total	3,069	4,042	'
Depreciation expense	1,126	1,331	1,035
Leaseholds [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property, plant and equipment, gross	1,749	1,716	'
Furniture [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property, plant and equipment, gross	957	952	'
Equipment [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property, plant and equipment, gross	1,552	1,473	'
Computers [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property, plant and equipment, gross	2,143	2,141	'
Buildings and Land [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property, plant and equipment, gross	$603	$603	'

Current_Accrued_Expenses_Detai

Current Accrued Expenses (Details) (USD $)	Dec. 31, 2013		Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012
Current Accrued Expenses [Abstract]	'		'
Compensation, excluding taxes	$1,866		$1,933
Deferred rent	485		443
Professional fees	360		1,438
Contract Research Organization	0		1,283
Other	1,029	[1]	693	[1]
Total accrued liabilities	$3,740		$5,790
Maximum percentage of current liabilities accrued (in hundredths)	5.00%		5.00%

[1]	Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at December 31, 2013 and 2012.

Restructuring_Charges_Details

Restructuring Charges (Details) (USD $)	12 Months Ended
Restructuring Charges (Details) (USD $)	Dec. 31, 2013
Restructuring Cost and Reserve [Line Items]	'
Percentage of current annual salary as cash retention bonus (in hundredths)	50.00%
Current Accrued Expenses [Member]	'
Restructuring Reserve [Roll Forward]	'
Severance and restructuring expenses, ending balance	1,600,000
Long-Term Accrued Expenses [Member]	'
Restructuring Reserve [Roll Forward]	'
Severance and restructuring expenses, ending balance	400,000
Operating Expense [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Number of positions eliminated	50
Severance costs	4,000,000
Restructuring Reserve [Roll Forward]	'
Severance and restructuring expenses, beginning balance	3,974,000
Restructuring expenses paid by December 31, 2013	-1,955,000
Severance and restructuring expenses, ending balance	2,019,000

Assets_and_Liabilities_Measure2

Assets and Liabilities Measured at Fair Value (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Input	Dec. 31, 2012	Dec. 31, 2011
Assets and Liabilities Measured at Fair Value [Abstract]	'	'	'
Number of inputs used for valuation of warrants	6	'	'
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Roll Forward]	'	'	'
Beginning balance	$3,427	$2,439	$18,005
Total change in the fair value of the liability included in earnings	-2,756	-2,159	-15,566
Fair value of warrants issued	'	4,055	'
Fair value of warrants issued, exercised and/or expired	1,639	-908	'
Ending balance	2,310	3,427	2,439
Recurring [Member] \| Derivative instruments liabilities [Member]	'	'	'
Liabilities [Abstract]	'	'	'
Total Liabilities	2,310	3,427	'
Recurring [Member] \| Derivative instruments liabilities [Member] \| Level 1 [Member]	'	'	'
Liabilities [Abstract]	'	'	'
Total Liabilities	0	0	'
Recurring [Member] \| Derivative instruments liabilities [Member] \| Level 2 [Member]	'	'	'
Liabilities [Abstract]	'	'	'
Total Liabilities	0	0	'
Recurring [Member] \| Derivative instruments liabilities [Member] \| Level 3 [Member]	'	'	'
Liabilities [Abstract]	'	'	'
Total Liabilities	2,310	3,427	'
Recurring [Member] \| Money market funds [Member]	'	'	'
Assets [Abstract]	'	'	'
Total Assets	1,956	1,967	'
Recurring [Member] \| Money market funds [Member] \| Level 1 [Member]	'	'	'
Assets [Abstract]	'	'	'
Total Assets	1,956	1,967	'
Recurring [Member] \| Money market funds [Member] \| Level 2 [Member]	'	'	'
Assets [Abstract]	'	'	'
Total Assets	0	0	'
Recurring [Member] \| Money market funds [Member] \| Level 3 [Member]	'	'	'
Assets [Abstract]	'	'	'
Total Assets	$0	$0	'

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)

1 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

3 Months Ended

31-May-12

Jul. 31, 2011

Jun. 30, 2009

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2008

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

31-May-12

Dec. 31, 2013

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

31-May-12

Dec. 31, 2013

Jun. 30, 2009

Dec. 31, 2013

Oct. 28, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2010

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2010

Oct. 28, 2013

Dec. 31, 2013

Oct. 28, 2013

Dec. 31, 2013

Mar. 13, 2013

Dec. 31, 2012

Dec. 31, 2013

Mar. 31, 2013

Stock Options [Member]

Restricted Stock [Member]

2004 Stock Incentive Plan [Member]

2009 Stock Incentive Plan [Member]

Cowen and Company, LLC [Member]

Terrapin Opportunity, L.P. [Member]

Minimum [Member]

Maximum [Member]

2012 Warrants [Member]

2009 Warrants [Member]

Warrants [Member]

2013 Warrants [Member]

Sales Agreement March 2013 [Member]

CEFF [Member]

Sales Agreement December 2011 [Member]

Selling, General and Administrative [Member]

Research and Development [Member]

Selling, General and Administrative [Member]

Research and Development [Member]

Stock Options [Member]

Minimum [Member]

Maximum [Member]

Terrapin Opportunity, L.P. [Member]

Cowen and Company, LLC [Member]

Terrapin Opportunity, L.P. [Member]

Cowen and Company, LLC [Member]

Stock Issuances [Abstract]

Sale of stock, net of expenses (in shares)

15,300,000

5,000,000

900,000

3,900,000

5,600,000

21,000,000

16,400,000

14,200,000

Warrants issued (in shares)

4,600,000

1,000,000

9,400,000

Proceeds from issuance of private placement

$21,500,000

$3,000,000

$20,900,000

$9,000,000

$7,500,000

$5,000,000

$2,100,000

Amount available under committed equity financing facility

50,000,000

23,900,000

Estimated fair value allocated to warrants issued

3,400,000

2,200,000

1,900,000

Warrants exercisable per share price (in dollars per share)

$0.16

$3.44

$0.44

$3.60

$0.44

Number of warrants outstanding (in shares)

4,400,000

1,000,000

14,871,891

5,642,580

2,512,934

9,400,000

Net proceeds from issuance of private placement

21,100,000

2,700,000

Term period for warrants

'3 years

'5 years

Net proceeds from issuance of common stock

23,500,000

20,800,000

39,800,000

8,900,000

6,900,000

4,800,000

Shares available under program (in shares)

Common stock, par value under sales agreement (in dollars per share)

$0.01

Amount to be purchased by party under agreement

35,000,000

Term of purchase agreement

'24 months

Derivative instrument income

410,000

-497,000

5,115,000

-2,272,000

1,134,000

446,000

917,000

-338,000

2,800,000

Derivative instrument liabilities

2,300,000

Fair value assumptions used to determine the value of warrants [Abstract]

Expected volatility (in hundredths)

106.77%

128.50%

91.00%

Risk free interest rate (in hundredths)

0.26%

0.10%

2.00%

Expected life (in years)

'1 year 4 months 28 days

'0 years 5 months 12 days

'5 years

Warrants outstanding [Roll Forward]

Outstanding, beginning of period (in shares)

5,642,580

2,512,934

Issued (in shares)

9,432,000

6,523,120

Exercised (in shares)

-202,689

-2,975,457

Expired (in shares)

-418,017

Outstanding, end of period (in shares)

4,400,000

1,000,000

14,871,891

5,642,580

2,512,934

9,400,000

Warrants, Exercise Price per Share [Roll Forward]

Outstanding, beginning of period (in dollars per share)

$3.44

$0.16

$3.44

$3.60

$0.44

$3.60

Issued (in dollars per share)

$1.49

$3.03

Exercised (in dollars per share)

$1.49

$1.65

Outstanding, end of period (in dollars per share)

$0.16

$3.44

$0.44

$3.60

$0.44

Warrants, Weighted Average Exercise Price [Roll Forward]

Outstanding, beginning of period (in dollars per share)

$1.20

$3.51

Issued (in dollars per share)

$0.44

$1.65

Exercised (in dollars per share)

$1.20

$1.49

Expired (in dollars per share)

$1.49

Outstanding, end of period (in dollars per share)

$0.34

$1.20

$3.51

Weighted average remaining life

'3 years 6 months 4 days

'2 years 2 months 26 days

'1 year 5 months 12 days

'2 years 5 months 12 days

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares reserved for the issuance (in shares)

3,000,000

4,200,000

6,500,000

Increased number of shares (in shares)

2,300,000

Term of options

'10 years

Stock Options, Number of Options [Roll Forward]

Outstanding, beginning of period (in shares)

4,788,887

4,129,749

3,760,650

Granted (in shares)

2,085,717

1,207,452

671,326

Expired (in shares)

-270,000

-420,000

-120,000

Forfeited (in shares)

-2,569,461

-128,314

-136,900

Exercised (in shares)

-45,327

Outstanding, end of period (in shares)

4,035,143

4,788,887

4,129,749

3,760,650

Exercisable (in shares)

2,136,785

Stock Options, Exercise Price per Share [Roll Forward]

Outstanding, beginning of period (in dollars per share)

$1.23

$15.54

Granted (in dollars per share)

$0.30

$1.43

$2.13

$4.60

$9.18

Expired (in dollars per share)

$1.23

$1.88

$3.28

$1.87

$5.85

$3.28

Forfeited (in dollars per share)

$0.38

$2.26

$1.40

$12.34

$9.18

$9.93

Exercised (in dollars per share)

$2.44

$3.28

Outstanding, end of period (in dollars per share)

$0.30

$1.23

$15.54

Exercisable (in dollars per share)

$1.24

$15.54

Stock Options, Weighted Average Exercise Price [Roll Forward]

Outstanding, beginning of period (in dollars per share)

$4.79

$5.09

$4.88

Granted (in dollars per share)

$1.09

$3.80

$5.72

Expired (in dollars per share)

$1.53

$4.81

$3.28

Forfeited (in dollars per share)

$3.97

$5.05

$4.65

Exercised (in dollars per share)

$3.18

Outstanding, end of period (in dollars per share)

$3.62

$4.79

$5.09

$4.88

Exercisable (in dollars per share)

$5.68

Stock Options, Weighted Average Remaining Life Years [Abstract]

Outstanding

'2 years 1 month 17 days

'6 years 10 months 17 days

'6 years 4 months 17 days

'6 years 7 months 24 days

Exercisable

'5 years 6 months 22 days

Assumptions used to determine the fair value of stock options [Abstract]

Weighted average risk-free interest rate (in hundredths)

1.30%

1.11%

2.07%

Weighted average expected volatility (in hundredths)

92.31%

79.89%

74.64%

Expected volatility (in hundredths)

86.16%

77.37%

73.88%

97.21%

84.81%

79.11%

Dividend yield (in hundredths)

0.00%

Weighted average expected option term

'5 years 7 months 28 days

'6 years 2 months 1 day

'6 years

Weighted average grant date fair value (in dollars per share)

$0.81

$2.59

$3.79

Non-vested Options, Number of Options [Roll Forward]

Non-vested, beginning of period (in shares)

1,683,352

1,158,368

Granted (in shares)

2,085,717

1,207,452

Vested (in shares)

-686,232

-570,518

Forfeited (in shares)

-1,184,479

-111,950

Non-vested, end of period (in shares)

1,898,358

1,683,352

1,158,368

Non-vested Options, Weighted Average Fair Value [Roll Forward]

Non-vested, beginning of period (in dollars per share)

$4.68

$6.44

Granted (in dollars per share)

$1.09

$3.80

Vested (in dollars per share)

$5.38

$6.38

Forfeited (in dollars per share)

$3.37

$4.79

Non-vested, end of period (in dollars per share)

$1.30

$4.68

$6.44

Additional compensation expense relating to stock options

600,000

Additional compensation expense relating to restricted stock

100,000

Remaining average recognition period for unrecognized compensation expense

'1 year 3 months

'0 years 8 months 12 days

Aggregate intrinsic value of options outstanding and exercisable

Closing stock price (in dollars per share)

$0.26

Restricted Stock, Number of Shares [Roll Forward]

Outstanding, beginning of period (in shares)

501,468

193,532

Granted (in shares)

276,250

429,720

Vested (in shares)

-313,395

-100,751

Forfeited (in shares)

-138,601

-21,033

Outstanding, end of period (in shares)

325,722

501,468

193,532

Restricted Stock, Weighted Average Grant Date Fair Value [Roll Forward]

Non-vested, beginning of period (in dollars per share)

$3.26

$5.84

Granted (in dollars per share)

$0.42

$2.83

Vested (in dollars per share)

$2.57

$6.18

Forfeited (in dollars per share)

$4.32

$4.39

Non-vested, end of period (in dollars per share)

$1.05

$3.26

$5.84

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Compensation expense recognized granted to employees

$200,000

$2,800,000

$3,600,000

$200,000

$1,700,000

$2,200,000

$1,100,000

$1,400,000

$200,000

$1,000,000

$600,000

$200,000

$700,000

$500,000

$300,000

$100,000

Loan_and_Security_Agreement_De

Loan and Security Agreement (Details) (Silicon Valley Bank [Member], USD $)	12 Months Ended
	Dec. 31, 2013
Silicon Valley Bank [Member]	'
Line of Credit Facility [Line Items]	'
Loan and security agreement	'4 years
Credit agreement, revolving credit facility	$20,000,000
Line of credit facility, covenant terms	'In order to draw down on the facility, the Company will need to have at least the greater of (i) $15,000,000 in cash and cash equivalents in its account with SVB plus the amount of all outstanding obligations of the Company owed to SVB and (ii) trailing 3 months Cash Burn (as defined in the Credit Agreement) plus the amount of all outstanding obligations of the Company owed to SVB.
Cash and cash equivalents	$15,000,000

Commitments_Details

Commitments (Details)

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

USD ($)

Office Space in New York, New York, Initial Lease [Member]

Office Space in New York, New York, Lease Amendment [Member]

Office Space in New York, New York, Initial Lease and Lease Amendment [Member]

Facility lease agreement [Member]

Country Club Road lease agreement [Member]

Park Road lease agreement [Member]

Delcath's European headquarters lease agreement [Member]

USD ($)

Year 1 [Member]

Year 2 [Member]

Year 3 [Member]

Year 4 [Member]

Year 5 [Member]

Years Thereafter [Member]

USD ($)

sqft

Year 1 [Member]

Year 2 [Member]

Year 3 [Member]

Year 4 [Member]

Year 5 [Member]

sqft

USD ($)

sqft

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

Operating Leased Assets [Line Items]

Square footage of office space (in square feet)

8,629

10,320

18,000

6,000

19,200

Expansion option, additional square footage of office space (in square feet)

8,629

Annual base rent payment in years 1-3 and first half of year 4

$457,337

Annual base rent payment in second half of year 4 and years 5-7

491,853

Additional square footage of office space leased under exercise of option right (in square feet)

8,629

Lease expiration date

31-Mar-21

Annual base rent payment in years 1-5

504,078

Annual base rent payment in years 6-11

547,533

Future minimum lease payments under all operating leases [Abstract]

2014

1,469,000

2015

1,338,000

2016

1,183,000

2017

1,052,000

2018

1,091,000

Total future minimum payments due

6,133,000

Operating lease term

'3 years

'1 year

'10 years

Annual base rent

543,627

961,000

970,000

996,000

1,000,000

1,100,000

216,000

42,000

146,009

106,051

185,830

134,974

219,015

159,077

252,198

183,179

252,198

183,179

Delivery time frame of written notice, minimum

'6 months

Purchase price which commenced on September 1, 2009

440,000

Rent expense

1,500,000

1,200,000

Letter of credit [Abstract]

Minimum letter of credit amount required to be maintained under lease agreement

$881,297

Expiration date of letter of credit

1-Feb-15

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
Income Taxes (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Provision for income taxes [Abstract]	'	'	'	'	'
Income taxes using U.S. federal statutory rate	($10,309,000)	($17,621,000)	($10,501,000)	'	'
Amortization of Gain on IP Migration	781,000	754,000	0	'	'
State income taxes, net of federal benefit	-1,390,000	-4,299,000	-3,418,000	'	'
Foreign rate differential	2,761,000	3,716,000	52,000	'	'
Valuation allowance	7,683,000	17,561,000	20,563,000	15,000,000	5,900,000
Derivative charge	-937,000	-734,000	-5,292,000	'	'
Stock option exercises and cancellations	1,589,000	310,000	102,000	'	'
Research and development credits	-1,090,000	326,000	-1,633,000	'	'
Other	912,000	-13,000	127,000	'	'
Total	0	0	0	'	'
Deferred tax assets [Abstract]	'	'	'	'	'
Employee compensation accruals	4,077,000	6,176,000	'	'	'
Accrued liabilities	870,000	299,000	'	'	'
Research tax credits	3,472,000	2,382,000	'	'	'
Other	79,000	31,000	'	'	'
Net operating losses	71,874,000	63,765,000	'	'	'
Total deferred tax assets	80,372,000	72,653,000	'	'	'
Deferred tax liability [Abstract]	'	'	'	'	'
Total deferred tax liabilities	0	0	'	'	'
Valuation allowance	80,372,000	72,653,000	'	'	'
Net deferred tax assets	0	0	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'	'
Percentage of valuation allowance (in hundredths)	100.00%	'	'	'	'
Valuation allowance increased	7,683,000	17,561,000	20,563,000	15,000,000	5,900,000
Tax benefit related to the exercise of non qualified stock options	1,000,000	'	'	'	'
Federal [Member]	'	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'	'
Operating loss carryforwards	158,400,000	138,100,000	'	'	'
Operating loss carryforwards, amount subject to limitations	8,600,000	'	'	'	'
Operating loss carryforwards, annual limitation	123,000	'	'	'	'
Operating loss carryforwards, net of limitations	152,300,000	'	'	'	'
Federal [Member] \| Minimum [Member]	'	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'	'
Operating loss carryforwards, expiration dates	'2018	'	'	'	'
Federal [Member] \| Maximum [Member]	'	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'	'
Operating loss carryforwards, expiration dates	'2033	'	'	'	'
State and city [Member]	'	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'	'
Operating loss carryforwards	268,800,000	231,000,000	'	'	'
Operating loss carryforwards, expiration dates	'2033	'	'	'	'
Foreign [Member]	'	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'	'
Operating loss carryforwards	$19,000,000	$17,400,000	'	'	'

Quarterly_Financial_Data_Unaud2

Quarterly Financial Data (Unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Data (Unaudited) [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Operating loss	($5,526)	($6,702)	($10,587)	($10,202)	($11,825)	($12,175)	($15,316)	($14,554)	($33,019)	($53,871)	($46,456)
Change in fair value of warranty liability, net	410	-497	5,115	-2,272	1,134	446	917	-338	2,800	'	'
Net loss	($4,792)	($7,206)	($5,482)	($12,845)	($10,657)	($11,813)	($14,512)	($14,889)	($30,324)	($51,868)	($30,885)
Basic and diluted loss per share (in dollars per share)	($0.04)	($0.07)	($0.06)	($0.15)	($0.14)	($0.18)	($0.26)	($0.31)	($0.30)	($0.85)	($0.68)

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	1 Months Ended			12 Months Ended			0 Months Ended		2 Months Ended
	31-May-12	Jul. 31, 2011	Jun. 30, 2009	Dec. 31, 2008	Dec. 31, 2013	Dec. 31, 2012	Feb. 24, 2014	Feb. 24, 2014	Feb. 28, 2013	Mar. 11, 2013
							Minimum [Member]	Maximum [Member]	Subsequent Event [Member]	Subsequent Event [Member]
									Sales Agreement [Member]	Sales Agreement [Member]
Subsequent Event [Line Items]	'	'	'	'	'	'	'	'	'	'
Common stock sold through the program (in shares)	15,300,000	5,000,000	900,000	3,900,000	'	'	'	'	16,000,000	'
Proceeds from issuance of common stock	'	$23,500,000	'	'	'	'	'	'	$4,400,000	'
Remaining value of common stock	'	'	'	'	$1,343,000	$768,000	'	'	'	$40,400,000
Reverse stock split ratio	'	'	'	'	'	'	0.0625	0.125	'	'